UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

Nucleic acids research, 2016-06, Vol.44 (11), p.e108

2016

Volltextzugriff (PDF)

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Clinical cancer research, 2020-05, Vol.26 (9), p.2176-2187

2020

Volltextzugriff (PDF)

Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer

Nature communications, 2022-03, Vol.13 (1), p.1667-1667, Article 1667

2022

Volltextzugriff (PDF)

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Molecular cancer therapeutics, 2016-11, Vol.15 (11), p.2563-2574

2016

Volltextzugriff (PDF)

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Nature communications, 2019-11, Vol.10 (1), p.5167-19, Article 5167

2019

Volltextzugriff (PDF)

Defining actionable mutations for oncology therapeutic development

Nature reviews. Cancer, 2016-05, Vol.16 (5), p.319

2016

Volltextzugriff (PDF)

Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets

BMC cancer, 2022-01, Vol.22 (1), p.13-13, Article 13

2022

Volltextzugriff (PDF)

Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort

BMC cancer, 2022-05, Vol.22 (1), p.587-587, Article 587

2022

Volltextzugriff (PDF)

Looking beyond the cancer cell for effective drug combinations

Genome medicine, 2016-11, Vol.8 (1), p.125-125, Article 125

2016

Volltextzugriff (PDF)

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Cancer research (Chicago, Ill.), 2010-03, Vol.70 (6), p.2264-2273

2010

Volltextzugriff (PDF)

DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy

NPJ digital medicine, 2021-02, Vol.4 (1), p.14-14, Article 14

2021

Volltextzugriff (PDF)

Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs

BMC genomics, 2016-01, Vol.17 (51), p.65-65, Article 65

2016

Volltextzugriff (PDF)

A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates

eLife, 2020-12, Vol.9

2020

Volltextzugriff (PDF)

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

NPJ precision oncology, 2022-12, Vol.6 (1), p.95-95, Article 95

2022

Volltextzugriff (PDF)

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum

Oncotarget, 2017-11, Vol.8 (59), p.99237-99244

2017

Volltextzugriff (PDF)

RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib

PloS one, 2013-06, Vol.8 (6), p.e66003

2013

Volltextzugriff (PDF)

Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors

NPJ systems biology and applications, 2024-06, Vol.10 (1), p.68-15, Article 68

2024

Volltextzugriff (PDF)

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Nature communications, 2019-05, Vol.10 (1), p.1-22, Article 2030

2019

Volltextzugriff (PDF)

Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens

Patterns (New York, N.Y.), 2020-08, Vol.1 (5), p.100065, Article 100065

2020

Volltextzugriff (PDF)

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Cancer research (Chicago, Ill.), 2015-06, Vol.75 (12), p.2489-2500

2015

Volltextzugriff (PDF)

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells

Science signaling, 2011-03, Vol.4 (166), p.ra17

2011

Volltextzugriff (PDF)

A pan-cancer organoid platform for precision medicine

Cell reports (Cambridge), 2021-07, Vol.36 (4), p.109429-109429, Article 109429

2021

Volltextzugriff (PDF)

Privacy preserving validation for multiomic prediction models

Briefings in bioinformatics, 2022-05, Vol.23 (3)

2022

Volltextzugriff (PDF)

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

Nature communications, 2024-06, Vol.15 (1), p.4871-21, Article 4871

2024

Volltextzugriff (PDF)

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer

Cancer research (Chicago, Ill.), 2018-12, Vol.78 (23), p.6691-6702

2018

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(53)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(29)
Humans
(26)
Oncology
(19)
Cancer
(12)
Cell Line, Tumor
(12)
Mutation
(12)
Tumors
(11)
Female
(10)
Neoplasms - Genetics
(10)
Animals
(8)
Biomarkers
(7)
Mice
(7)
Carcinoma, Non-Small-Cell Lung - Genetics
(5)
Cell Biology
(5)
Gene Expression
(5)
Lung Neoplasms - Genetics
(5)
Male
(5)
Neoplasms - Drug Therapy
(5)
Patients
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Defining actionable mutations for oncology therapeutic development

Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets

Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort

Looking beyond the cancer cell for effective drug combinations

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy

Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs

A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum

RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib

Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells

A pan-cancer organoid platform for precision medicine

Privacy preserving validation for multiomic prediction models

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer

Suchergebnisse filtern